LOUISVILLE, Ky., Aug. 22, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG) announced today that the Company will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference.
Company management will present on Friday, September 6th at 12:20pm ET. A live and archived webcast of the event will be available on the “Event & Presentations” section of the BrightSpring investor relations website at https://ir.brightspringhealth.com/.
About BrightSpring Health Services
BrightSpring Health Services is the parent company of leading service lines that provide integrated home- and community-based pharmacy and health solutions for complex populations in need of specialized and/or chronic care. Through the company’s service lines, including pharmacy, primary care and home health care, and rehabilitation and behavioral health, we provide comprehensive care and clinical solutions in all 50 states to over 400,000 customers, clients and patients daily. For more information, visit www.brightspringhealth.com.
Contact
Investor Relations:
David Deuchler, CFA
Gilmartin Group LLC
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Leigh White
This email address is being protected from spambots. You need JavaScript enabled to view it.
502.630.7412
| Last Trade: | US$16.96 |
| Daily Change: | -0.80 -4.50 |
| Daily Volume: | 1,306,458 |
| Market Cap: | US$2.950B |
March 06, 2025 November 26, 2024 November 06, 2024 November 01, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
